MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00535-025-02216-0

Медицинская библиотека · Journal of gastroenterology · 2025

First-line biologics as a treatment for ulcerative colitis: a multicenter randomized control study.

Naganuma Makoto, Shiga Hisashi, Shimoda Masayuki, Matsuura Minoru, Takenaka Kento, Fujii Toshimitsu, Yamamoto Shojiro, Matsubayashi Mao, Kobayashi Taku, Aoyama Nobuo, Saito Daisuke, Yokoyama Kaoru, Moriya Kei, Tsuchiya Kiichiro, Shibui Shunsuke, Kawamoto Ami, Shimizu Hiromichi, Okamoto Ryuichi, Sakamoto Kazuki, Yaguchi Katsuki, Kunisaki Reiko, Akiyama Shintaro, Hayashi Ryohei, Hasui Keisuke, Kanmura Shuji, Bamba Shigeki, Mishima Yoshiyuki, Kakimoto Kazuki, Sugimoto Shinya, Nakazawa Atsushi, Abe Takayuki, Ogata Haruhiko, Hisamatsu Tadakazu, Collaborators of the Study

СтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Despite the availability of several biologics for ulcerative colitis (UC), there remains a critical need to identify first-line treatment biologics. The superiority of infliximab (IFX) over vedolizumab (VED) and ustekinumab (UST) was evaluated as initial UC treatments in patients with biologic-naïve UC.

METHODS

This multicenter, randomized control trial was conducted across 20 Japanese medical institutions. An independent center randomly allocated patients with UC (Mayo score ≥ 6) who had not previously used biologics to three treatment groups (IFX, VED, UST). The primary endpoint was the clinical remission (CR) rate at week 12, with other endpoints including the treatment continuation rate at week 26 and adverse events (AEs).

RESULTS

From May 2021 to June 2023, 107 cases were registered, including 104 for safety and 97 for efficacy evaluation. CR rate at week 12 was 36.4% (95%CI:20.4-54.9), 32.4% (95%CI:17.4-50.5) and 43.3% (95%CI:25.5-62.6) in IFX, VED, and UST group, respectively. Continuation rates at week 26 were 50.0%(IFX), 58.3% (VED), and 82.4% (UST). AEs related to study medication were 14.7% (IFX), 16.7% (VED), and 5.9% (UST). Predictors for CR at week 12 were thiopurine use in IFX (p = 0.04), lower baseline Mayo score (p = 0.007), and lower Patient report outcome 2 (p = 0.003) at week 2 in VED.

CONCLUSION

Due to small sample size, it is challenging to make conclusions for main endpoints from this study while our study suggested that use of thiopurines in IFX group and lower activity at enrollment in VED group may enhance treatment efficacy. (jRCT1031200329; available at https://jrct.niph.go.jp/ ).

Для цитирования: Naganuma Makoto, Shiga Hisashi, Shimoda Masayuki, Matsuura Minoru, Takenaka Kento, Fujii Toshimitsu, Yamamoto Shojiro, Matsubayashi Mao, Kobayashi Taku, Aoyama Nobuo, Saito Daisuke, Yokoyama Kaoru, Moriya Kei, Tsuchiya Kiichiro, Shibui Shunsuke, Kawamoto Ami, Shimizu Hiromichi, Okamoto Ryuichi, Sakamoto Kazuki, Yaguchi Katsuki, Kunisaki Reiko, Akiyama Shintaro, Hayashi Ryohei, Hasui Keisuke, Kanmura Shuji, Bamba Shigeki, Mishima Yoshiyuki, Kakimoto Kazuki, Sugimoto Shinya, Nakazawa Atsushi, Abe Takayuki, Ogata Haruhiko, Hisamatsu Tadakazu, Collaborators of the Study. First-line biologics as a treatment for ulcerative colitis: a multicenter randomized control study.. Journal of gastroenterology. 2025. DOI: 10.1007/s00535-025-02216-0.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.